Prospects for the development of new drugs for the therapy of respiratory diseases

Drugs of Today

Volumn 32, Issue 4, 1996, Pages 295-311

  Whelan, C J ^a  

^a UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDRO 3 HYDROXY 2,2 DIMETHYL 4 (3 OXO 1 CYCLOPENTEN 1 YLOXY) 2H 1 BENZOPYRAN 6 CARBONITRILE; APAFANT; AZELASTINE; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CETIRIZINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CROMAKALIM; FLUTICASONE PROPIONATE; FORMOTEROL; GLUCOCORTICOID; INTERLEUKIN 8; IPRATROPIUM BROMIDE; MIFEPRISTONE; MODIPAFANT; PHOSPHODIESTERASE; POTASSIUM CHANNEL AFFECTING AGENT; SALBUTAMOL; SALMETEROL; SIGUAZODAN; TERBUTALINE; THEOPHYLLINE; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; UNCLASSIFIED DRUG; VAPIPROST; ZAFIRLUKAST; ZARDAVERINE;

ADULT RESPIRATORY DISTRESS SYNDROME; ASTHMA; BRONCHITIS; DRUG EFFICACY; DRUG SAFETY; EMPHYSEMA; HUMAN; INHALATIONAL DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; RESPIRATORY TRACT DISEASE; REVIEW;

EID: 0029897335     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Review

References (133)

1. Meneely, G.R., Renzetti, A.D. Jr., Steele, J.D., Wyatt, J.P., Harris, H.W. Chronic bronchitis, asthma and pulmonary emphysema. A statement by the committee on diagnostic standards for nontuberculous respiratory diseases. Definitions and classification of chronic bronchitis, asthma and pulmonary emphysema. Amer Rev Respir Dis 1962, 85: 762-8.
2. Hopewell, P.C., Murray, J.F. The adult respiratory distress syndrome. Annu Rev Med 1876, 27: 343-56.
3. Editorial. Respiratory disease in England and Wales. Thorax 1988, 43: 949-54.
4. McFadden, E.R. Jr., Gilbert, I.A. Asthma. New Engl J Med 1992 327: 1928-37.
5. Goldstein, R.A., Paul, W.E., Metcalfe, D.D., Busse, W.W., Reece, E.R. Asthma. Ann Intern Med 1994, 121: 698-708.
6. Barnes, P.J. Milestones in asthma treatment. Eur Respir Rev 1991, 1: 247-50.
7. Wanner, A. State of the art. Clinical aspects of mucociliary transport. Amer Rev Respir Dis 1977, 116: 73-125.
8. Jeffery, P.K. Morphology of the airway wall in asthma and chronic obstructive pulmonary disease. Amer Rev Respir Dis 1991, 143: 1152-8.
9. Tattersfield, A.E., McNicol, M.W. (Eds.). Respiratory Disease. Springer-Verlag: Heidelberg 1996.
10. Lofdahl, C-G., Svedmyr, N. Beta-agonists - Friends or foes. Eur Respir J 1991, 4: 1161-5.
11. Svedmyr, N. Asthma treatment pharmacological principles and mechanisms of drug action. Scand J Respir Dis 1977, 10: 13-24.
12. Barnes, P.J., Adcock, I. Anti-inflammatory actions of steroids: Molecular mechanisms. Trends Pharmacol Sci 1993, 14: 436-41.
13. Lipworth, B.J. Clinical pharmacology of corticosteroids in bronchial asthma. Pharmacol Ther 1993, 58: 173-209.
14. Laitinen, L.A., Laitinen, A., Haahtela, T. Airway mucosal inflammation even in patients with newly diagnosed asthma. Amer Rev Respir Dis 1993, 147: 697-704.
15. Bradley, B.L., Azzawi, M., Jacobson, M. et al. Eosinophils, T-lymphocytes, mast cells, neutrophils and macrophages in bronchial biopsy specimens from atopic subjects with asthma: Comparison with biopsy specimens from atopic subjects without asthma and normal control subjects and relationship to bronchial hyperresponsiveness. J Allergy Clin Immunol 1991, 88: 661-74.
16. Bousquet, J., Chanez, P., Vignola, A.M., Lacoste, J-Y., Michel, F.B. Eosinophil inflammation in asthma. Crit Care Med 1994, 150: S33-8.
17. Barnes, P.J. New drugs for asthma. Eur Respir J 1992, 5: 1126-36.
18. Brittain, R.T., Dean, C.M., Jack, D. Sympathomimetic bronchodilator drugs. Pharmacol Ther B 1976, 2: 423-62.
19. Tattersfield, A.E. Bronchodilator drugs. Pharmacol Ther 1982, 17: 299-313.
20. Cushley, M., Holgate, S.T. Theophylline. In: Development of Antiasthma Drugs. Buckle, D.R., Smith, H. (Eds.). Butterworth: London 1984, 205-23.
21. Woodcock, A.A., Johnson, M.A., Geddes, D.M. Theophylline prescribing, serum concentrations and toxicity. Lancet 1983, II: 610-2.
22. Kuehl, F.A., Zanetti, M.E., Soderman, D.O., Milter, D.K., Ham, E.A. Cyclic AMP-dependent regulation of lipid mediators in white cells. A unifying concept for explaining the efficacy of theophylline in asthma. Amer Rev Respir Dis 1987, 136: 210-3.
23. Murray, K.J., Eden, R.J., England, P.J. et al. Potential use of selective phosphodiesterase inhibitors in the treatment of asthma. In: New Drugs for Asthma Therapy. Anderson, G.P., Chapman, I.D., Morley, J. (Eds.). Birkhäuser: Basel 1991, 27-46.
24. Tomkinson, A., Karlsson, J-A., Raeburn, D. Comparison of the effects of selective inhibitors of phosphodiesterase types III and IV in airway smooth muscle with differing β-adrenoceptor subtypes. Brit J Pharmacol 1993, 108: 57-61.
25. Qian, Y., Naline, E., Karlsson, J-A., Raeburn, D., Advenier, C. Effects of rolipram and siguazodan on the human isolated bronchus and their interaction with isoprenaline and sodium nitroprusside. Brit J Pharmacol 1993, 109: 774-8.
26. Dent, G., Magnussen, H., Rabe, K.F. Cyclic nucleotide phosphodiesterases in the human lung. Lung 1994, 172: 129-46.
27. Giembycz, M.A., Dent, G. Prospects for selective cyclic nucleotide phosphodiesterase inhibitors in the treatment of bronchial asthma. Clin Exp Allergy 1992, 22: 337-44.
28. Underwood, D.C., Kotzer, C.J., Bochnowicz, S. et al. Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea-pigs. J Pharmacol Exp Ther 1994, 270: 250-9.
29. Elwood, W., Sun, J., Barnes, P.J., Giembycz, M.A., Chung, K.F. Inhibition of allergen-induced lung eosinophilia by type-III and combined type-III and IV-selective phosphodiesterase inhibitors in Brown-Norway rats. Inflammation Res 1995, 44: 83-6.
30. 2-adrenoceptor agonists in allergic inflammation. Clin Exp Allergy 1992, 22: 177-81.
31. Whelan, C.J., Johnson, M., Vardey, C.J. Comparison of the antiinflammatory properties of formoterol, salbutamol and salmeterol in guinea-pig lung and skin. Brit J Pharmacol 1993, 110: 613-8.
32. Twentyman, O.P., Finnerty, J.P., Harris, A., Palmer, J., Holgate, S.T. Protection against allergen-induced asthma by salmeterol. Lancet 1990, 336: 1338-42.
33. 2-agonist. J Allergy Clin Immunol 1992, 89: 844-9.
34. Buckle, D.R. Prospects for potassium channel activators in the treatment of airways obstruction. Pulmonary Pharmacol 1993, 6: 161-9.
35. Paciorek, P.M., Cowlrick, I.S., Spence, A.M., Taylor, J.C., Waterfall, J.F. Comparison of the bronchodilator properties of Ro 31-6930, lemakalim and salmeterol. Brit J Pharmacol 1990, 101: 592P.
36. Small, R.C., Berry, J.L., Burka, J.F. et al. Potassium channel activators and bronchial asthma. Clin Exp Allergy 1992, 22: 11-8.
37. Baird, A., Hamilton, T.C., Richards, D., Tasker, T., Williams, J. Cromakalim, a potassium channel activator, inhibits histamine induced bronchoconstriction in healthy volunteers. Brit J Clin Pharmacol 1988, 25: 114P.
38. Barnes, P.J., Chung, K.F., Page, C.P. Inflammatory mediators and asthma. Pharmacol Rev 1988, 40: 49-84.
39. 2, and other bronchoconstricting prostaglandins in the airways of subjects with mild asthma. Amer Rev Respir Dis 1990, 142: 126-32.
40. Holgate, S.T., Finnerty, J.P. Antihistamines in asthma. J Allergy Clin Immunol 1989, 83: 537-47.
41. Bernheim, J., Arendt, C., De Vos, C. Cetirazine more than an antihistamine? In: New Drugs for Asthma Therapy. Anderson, G.P., Chapman, I.D., Morley, J. (Eds.). Birkhäuser: Basel 1991, 269-93.
42. Szelenyi, I., Achterrath-Tuckermann, U., Schmidt, J., Minker, E., Paegelow, I., Werner, H. Azelastine: A multifaceted drug for asthma therapy. In: New Drugs for Asthma Therapy. Anderson, G.P., Chapman, I.D., Morley, J. (Eds.). Birkhäuser: Basel 1991, 295-311.
43. Chung, K.F. Pharmacology of airway inflammation in asthma. Lung 1990, 132-41.
44. 2 in asthma - Preclinical and clinical findings. In: New Drugs for Asthma Therapy. Anderson, G.P., Chapman, I.D., Morley, J. (Eds.). Birkhäuser: Basel 1991, 211-20.
45. Alabaster, V.A., Kier, R.F., Parry, M.J., de Souza, R.N. UK-74,505, a novel and selective PAFantagonist, exhibits potent and long-lasting activity in vivo. In: New Drugs for Asthma Therapy. Anderson, G.P., Chapman, I.D., Morley, J. (Eds.). Birkhäuser: Basel 1991, 221-7.
46. Spence, D.P.S., Johnston, S.L., Calverly, P.M.A. et al. The effect of the orally active platelet activating factor antagonist WEB 2086 in the treatment of asthma. Grit Care Med 1994, 149: 1142-8.
47. Kuitert, L.M., Angus, R.M., Barnes, N.C. et al. Effect of a novel platelet-activating factor antagonist, modipafant, in clinical asthma. Crit Care Med 1995, 151: 1331-5.
48. 4 receptor antagonist. Amer Rev Respir Dis 1992, 145: 746-9.
49. Hay, D.W.P., Torphy, T.J., Undem, B.J. Cysteinyl leukotrienes in asthma: Old mediators up to new tricks. Trends Pharmacol Sci 1995, 16: 304-9.
50. 4) receptor antagonist (MK-571) in patients with asthma. Amer Rev Respir Dis 1992, 146: 358-63.
51. Findlay, S.R., Barden, J.M., Easley, C.B., Glass, M. Effect of the oral leukotriene antagonist, ICI 204,219, on antigen-induced bronchoconstriction in subjects with asthma. J Allergy Clin Immunol 1992, 89: 1040-5.
52. Brattsand, R. Development of glucocorticosteroids with lung selectivity. In: Glucocorticoids and Mechanisms of Asthma. Hargreave, F.E., Hogg, J.C., Malo, J-L., Toogood, J.H. (Eds.). Excerpta Medica: Amsterdam 1988, 17-38.
53. Brattsand, R., Andersson, P.T., Edsbacker, S., Ryrfeldt, A. Development of glucocorticoids with lung selectivity. In: Advances in the Use of Inhaled Corticosteroids. Ellul-Micallef, R., Lam, K., Toogood, J.H. (Eds.). Excerpta Medica: Amsterdam 1987, 60-78.
54. McFadden, E.R. Jr. Dosages of corticosteroids in asthma. Amer Rev Respir Dis 1993, 147: 1306-10.
55. Harding, S.M. The human pharmacology of fluticasone propionate. Respir Med 1990, 84: 25-9
56. Dahl, R., Lundback, B., Malo, J-E. et al. A dose-ranging study of fluticasone propionate in adult patients with moderate asthma. Chest 1993, 104: 1352-8.
57. Holliday, S.M., Faulds, D., Sorkin, E.M. Inhaled fluticasone propionate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma. Drugs 1994, 47: 318-31.
58. Beato, M. Gene regulation by steroid hormones. Cell 1989, 56: 335-44.
59. Thompson, A.B., Mueller, M.B., Heires, A.J. et al. Aerosolized beclomethasone in chronic bronchitis. Improved pulmonary function and diminished airway inflammation. Amer Rev Respir Dis 1992, 146: 389-95.
60. Autelitano, D.J. Glucocorticoid regulation of c-fos and c-jun and transcription factor AP-1 in the AtT-20 corticotrope cell. J Neuroendocrinol 1994, 6: 627-37.
61. Favata, M.F., Bonak, V.A., Stradley, D.A., Trzaskos, J.M. Differential effects of steroid hormones on GRE-mediated transactivation and AP-1 suppression. Inflammation Res 1995, 44 (Suppl. 3): S221.
62. Simons, S.S. Jr., Oshima, H., Szapary, D. Higher levels of control: Modulation of steroid hormone-regulated gene transcription. Mol Endocrinol 1992, 6: 995-1002.
63. Whelan, C.J., Hughes, S.H., Wren, G.P.A. Inhibition of some aspects of acute inflammation of guinea-pig lung by intraperitoneal dexamethasone and mifepristone: Demonstration of agonist activity of mifepristone in the guinea-pig. Inflammation Res 1994, 44: 131-8.
64. Fanjul, A., Dawson, M.I., Hobbs, P.D. et al. A new class of retinoids with selective inhibition of AP-1 inhibits proliferation. Nature 1994, 372: 107-11.
65. Liu, J. FK-506 and cyclosporin, molecular probes for studying intracellular signal transduction. Immunol Today 1993, 14: 290-5.
66. Church, M.K. Cromoglycate like antiallergic drugs: A review. Med Actual/Drugs Today 1978, 14: 281-341.
67. Altounyan, R.E.C. Developments in the treatment of asthma with disodium cromoglycate (lomudol). Acta Allergol 1975, 30 (Suppl. 12): 65-86.
68. 2-like cells in the pathogenesis of airway allergic inflammation. Clin Exp Allergy 1993, 23: 360-9.
69. 2 cells: Functional properties, mechanism of regulation and role in disease. Lab Invest 1994, 70: 229-306.
70. Moser, R., Fehr, J., Bruijnzeel, P.L.B. IL-4 controls the selective endothelium-driven transmigration of eosinophils from allergic individuals. J Immunol 1992, 149: 1432-8.
71. Smith, C.H., Barker, J.N.W.N., Lee, T.H. Adhesion molecules in allergic inflammation. Amer Rev Respir Dis 1993, 148: S75-8.
72. Resnick, M.B., Weller, P.F. Mechanisms of eosinophil recruitment. Cell Mol Biol 1993, 8: 349-55.
73. Clutterbuck, E.J., Hirst, E.M.A., Sanderson, C.J. Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: Comparison and interaction with IL-1, IL-3, IL-6 and GM-CSF. Blood 1989, 73: 1504-12.
74. Collins, P.D., Marleau, S., Griffiths-Johnson, D.A., Jose, P.J., Williams, T.J. Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo. J Exp Med 1995, 182: 1169-74.
75. Masuyama, K., Jacobson, M.R., Rak, S. et al. Topical glucocorticoid (fluticasone propionate) inhibits cells expressing mRNA for interleukin-4 in the nasal mucosa in allergen-induced rhinitis. Immunology 1994, 82: 192-9.
76. Mauser, P.J., Pitman, A.M., Fernandez, X. et al. Effects of an antibody to interleukin-5 in a monkey model of asthma. Crit Care Med 1995, 152: 467-72.
77. Kung, T.T., Stelts, D.M., Zurcher, J.A. et al. Involvement of IL-5 in a murine model of allergic pulmonary inflammation: Prophylactic and therapeutic effect of an anti-IL-5 antibody. Cell Mol Biol 1995, 13: 360-5.
78. Furie, M.B., Randolph, G.J. Chemokines and tissue injury. Amer J Pathol 1995, 146: 1287-301.
79. Jose, P.J., Griffiths-Johnson, D.A., Collins, P.D. et al. Eotaxin: A potent eosinophil chemoattractant cytokine detected in a guinea-pig model of allergic airways inflammation. J Exp Med 1994, 179: 881-7.
80. Griffiths-Johnson, D.J., Collins, P.D., Rossi, A.G., Jose, P.J., Williams, T.J. The chemokine, eotaxin, activates guinea-pig eosinophils in vitro and causes their accumulation into the lung in vivo. Biochem Biophys Res Commun 1993, 197: 1167-72.
81. Weg, V.B., Williams, T.J., Lobb, R.R., Nourshargh, S. A monoclonal antibody recognising very late activation antigen-4 inhibits eosinophil accumulation in vivo. J Exp Med 1993, 177: 561-6.
82. Sanz, M-J., Lobb, R.R., Nourshargh, S. IL-4-induced eosinophil accumulation in rat skin is VCAM-1-dependent. Inflammation Res 1995, 44: S223.
83. Podolsky, D.K., Lobb, R., King, N. et al. Attenuation of colitis in the cotton top tamarin by anti-VLA-4 monoclonal antibody. Gastroenterology 1993, 104: A764.
84. Pretolani, M., Ruffie, C., Lapa e Silva, J-R., Joseph, D., Lobb, R.R., Vargaftig, B.B. Antibody to very late activation antigen 4 prevents antigen-induced bronchial hyperreactivity and cellular infiltration in the guinea pig airways. J Exp Med 1994, 180: 795-805.
85. 2-like bronchoalveolar T-lymphocyte population in atopic asthma. New Engl J Med 1992, 326: 298-304.
86. Barbadillo, C., Andreu, J.L., Mulero, J., Sánchez-Madrid, F. Anti-VLA-4 MAB prevents adjuvant arthritis in Lewis rats. Arthritis Rheumatism 1993, 36: S95.
87. Souness, J.E., Maslen, C., Webber, S. et al. Suppression of eosinophil function by RP73401, a potent and selective inhibitor of cyclic AMP specific phosphodiesterase: Comparison with rolipram. Brit J Pharmacol 1995, 115: 39-46.
88. Lagente, V., Moodley, I., Perrin, S., Mottin, G., Junien, J.L. Effects of isozyme selective phosphodiesterase inhibitors and theophylline on eosinophil infiltration in the guinea-pig lung. Brit J Pharmacol 1994, 112: 83P.
89. Hughes, B., Holbrook, M., Allen, R. et al. Suppression of antigen-induced airway responses and bronchial hyperresponsiveness by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type IV. Brit J Pharmacol 1995, 116: 6P.
90. Prabhakar, U., Lipshutz, D., O'Leary Bartus, J. et al. Characterization of cAMP-dependent inhibition of LPS-induced TNFα production by rolipram. A specific phosphodiesterase IV (PDE IV) inhibitor. Int J Immunopharmacol 1994, 16: 805-16.
91. Levine, S.J., Larivee, P., Logun, C., Angus, C.W., Shelhamer, J.H. Corticosteroids differentially regulate secretion of IL-6, IL-8 and G-CSF by a human bronchial epithelial cell line. Amer J Physiol 1993, 265: L360-8.
92. Barnes, P.J. Cytokines as mediators of chronic asthma. Crit Care Med 1994, 150: S42-9.
93. Tomkinson, A., Sharma, S., Souness, J., Raeburn, D. Effects of ibudilast on airways smooth muscle contraction in vitro and in vivo: Comparison with rolipram. Brit J Pharmacol 1993, 108: 73P.
94. 2-adrenoceptor agonist: Characterization of pharmacological activity in vitro and in vivo. Brit J Pharmacol 1991, 104: 665-71.
95. Polosa, R., Ng, W.H., Crimi, N. et al. Release of mast-cell-derived mediators after endobronchial adenosine challenge in asthma. Crit Care Med 1995, 151: 624-9.
96. Cronstein, B.N., Levin, R.L., Belanoff, J., Weissmann, G., Hirschhorn, R. Adenosine: An endogenous inhibitor of neutrophil-mediated injury to endothelial cells. J Clin Invest 1986, 78: 760-70.
97. Cronstein, B.N. Adenosine, an endogenous anti-inflammatory agent. J Appl Physiol 1994, 76: 5-13.
98. Rosengren, S., Bong, G.W., Firestein, G.S. Anti-inflammatory effects of an adenosine kinase inhibitor. Decreased neutrophil accumulation and vascular leakage. J Immunol 1995, 154: 5444-51.
99. Coates, J., Gurden, M.F., Harris, C., Kennedy, I., Sheehan, M.J., Strong, P. Adenosine receptor classification: Quo Vadimus. Nucleosides Nucleotides 1994, 13: 1953-76.
100. 3 receptor agonist APNEA induces bronchospasm. Brit J Pharmacol 1995, 114: 57P.
101. Evans, K.S., Coleman, R.A., Nials, A.T., Vardey, C.J. The antiinflammatory and behavioural, effects of phosphodiesterase inhibitors in the conscious rat. Brit J Pharmacol 1995, 116: 88P.
102. Pedersen, B., Dahl, R., Larsen, B.B., Venge, P. The effect of salmeterol on the early- and late-phase reaction to bronchial allergen and post-challenge variation in bronchial reactivity, blood eosinophils, serum eosinophil cationic protein and serum eosinophil protein X. Allergy 1993, 48: 377-82
103. Whelan, C.J., Johnson, M. Salmeterol, but not salbutamol, has anti-inflammatory actions in guinea pig skin. Brit J Pharmacol 1991, 102: 95P.
104. Johnson, M., Butchers, P.R., Coleman, R.A. et al. The pharmacology of salmeterol. Life Sci 1993, 52: 2131-43.
105. Ohnishi, T., Sur, S., Collins, D.S., Fish, J.E., Gleich, G.J., Peters, S.P. Eosinophil survival activity identified as interleukin-5 is associated with eosinophil recruitment and degranulation and lung injury twenty-four hours after segmental antigen lung challenge. J Allergy Clin Immunol 1993, 92: 607-15.
106. Warringa, R.A.J., Schweizer, R.C., Maikoe, T., Kuijper, P.H.M., Bruijnzeel, P.L.B., Koenderman, L. Modulation of eosinophil chemotaxis by interleukin-5. Cell Mol Biol 1992, 7: 631-6.
107. Wallen, N., Kita, H., Weiler, D., Gleich, G.J. Glucocorticoids inhibit cytokine-mediated eosinophil survival. J Immunol 1991, 147: 3490-5.
108. Fletcher, C., Peto, R. The natural history of chronic airflow obstruction. Brit Med J 1977, 1: 1645-8.
109. Hoshi, H., Ohno, I., Honma, M. et al. IL-5, IL-8 and GM-CSF immunostaining of sputum cells in bronchial asthma and chronic bronchitis. Clin Exp Allergy 1995, 25: 720-8.
110. Lacoste, J-Y., Bousquet, J., Chanez, P. et al. Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis, and chronic obstructive pulmonary disease. J Allergy Clin Immunol 1993, 92: 537-48.
111. Dunnill, M.S., Massarella, G.R., Anderson, J.A. A comparison of the quantitative anatomy of the bronchi in normal subjects, in status asthmaticus, in chronic bronchitis and in emphysema. Thorax 1969, 24: 176-9.
112. Higgins, B.G., Powell, R.M., Cooper, S., Tattersfield, A.E. Effect of salbutamol and ipratropium bromide on airway calibre and bronchial reactivity in asthma and chronic bronchitis. Eur Respir J 1991, 4: 415-20.
113. Heard, B.E., Hossain, S. Hyperplasia of bronchial muscle in asthma. J Pathol 1973, 110: 319-31.
114. Thompson, A.B., Daughton, D., Robbins, R.A., Ghafouri, M.A., Oehlerking, M., Rennard, S.I. Intraluminal airway inflammation in chronic bronchitis. Characterisation and correlation with clinical parameters. Amer Rev Respir Dis 1989, 140: 1527-37.
115. Stockley, R.A. Proteolytic enzymes, their inhibitors and lung diseases. Clin Sci 1983, 64: 119-26.
116. Cohn, L.A., Adler, K.B. Interactions between airway epithelium and mediators of inflammation. Exp Lung Res 1992, 18: 299-322.
117. 1-Antitrypsin: Molecular pathology, leukocytes, and tissue damage. J Clin Invest 1986, 78: 1427-31.
118. Stolk, J., Rudolphus, A., Davies, P. et al. Induction of emphysema and bronchial mucus cell hyperplasia by intratracheal instillation of lipopolysaccharide in the hamster. J Pathol 1992, 167: 349-56.
119. Janusz, M.J., Durham, S.L., Hare, C.M. et al. Pharmacological evaluation of selected orally active peptidyl inhibitors of human neutrophil elastase. J Pharm Pharmacol 1995, 275: 1223-30.
120. Cromwell, O., Hamid, Q., Corrigan, C.J. et al. Expression and generation of interleukin-8, IL-6 and granulocyte-macrophage colony-stimulating factor by bronchial epithelial cells and enhancement by IL-1B and tumor necrosis factor-α. Immunology 1992, 77: 330-7.
121. Kwon, O.J., Au, B.T., Collins, P.D., Baraniuk, J.N., Adcock, I.M., Chung, K.F. Inhibition of interleukin-8 expression by dexamethasone in human cultured airway epithelial cells. Immunology 1994, 81: 389-94.
122. Anisowicz, A., Messineo, M., Lee, S.W., Sager, R. An NF-χB-like transcription factor mediates IL-1/TNFα induction of growth in human fibroblasts. J Immunol 1991, 147: 520-7.
123. Bacon, K.B., Schall, T.J. Chemokines as mediators of inflammation. Int Arch Allergy Immunol 1996, 109: 97-109.
124. Thelen, M., Dewald, B., Baggiolini, M. Neutrophil signal transduction and activation of the respiratory burst. Physiol Rev 1993, 73: 797-821.
125. Hancock, W.W. Chemokines and the pathogenesis of T cell- dependent immune responses. Amer J Pathol 1996, 148: 681-4.
126. Hyers, T.M., Fowler, A.A. Adult respiratory distress syndrome: Causes, morbidity and mortality. Fed Proc 1986, 45: 25-9.
127. Bresler, M.J., Sternbach, G.L. The adult respiratory distress syndrome. Emergency Med Clin N Amer 1989, 7: 419-30.
128. Petty, T.L. ARDS: Redefinement of concept and redefinition. Amer Rev Respir Dis 1988, 138: 724.
129. 1 and nitroglycerin reduce pulmonary capillary pressure but worsen ventilation-perfusion distributions in patients with adult respiratory distress syndrome. Anesthesiology 1989, 601-6.
130. Miller, E.J., Cohen, A.B., Nagao, S. et al. Elevated levels of NAP-1/interleukin-8 are present in the airspaces of patients with the adult respiratory distress syndrome and are associated with increased mortality. Amer Rev Respir Dis 1992, 146: 427-32.
131. Weiland, J.E., Davis, W.B., Holter, J.F., Mohammed, J.R., Dorinsky, P.M., Gadek, J.E. Lung neutrophils and the adult respiratory distress syndrome. Clinical and pathophysiologic significance. Amer Rev Respir Dis 1986, 133: 218-25.
132. Demling, R.H. Current concepts on the adult respiratory distress syndrome. Circ Shock 1990, 30: 297-309.
133. Maunder, R.J., Hackman, R.C., Riff, E., Albert, R.K., Springmeyer, S.C. Occurrence of the adult respiratory distress syndrome in neutropenic patients. Amer Rev Respir Dis 1986, 133: 313-6.